The Phase II trial of recurrent acute cystitis is proceeding according to plan
SelectImmune Pharma is conducting a randomized single-center Phase II trial in patients with recurrent acute cystitis, investigating the effects of the IL-1 receptor antagonist (IL-1RA). The clinical trial is led by key opinion leaders in the field of urinary tract infection therapy in Giessen, Germany and at Lund University. The efficient study organization includes physicians, monitors, other clinical and laboratory staff. Patient recruitment is proceeding according to plan, and we envisage completion of enrolment by the end of this year (See the WHO registry at https://trialsearch.who.